Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreCoDe: Prasinezumab in Parkinson's Disease with Severe GBA Mutation
NCT07055087Phase 2Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2026
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of prasinezumab in Parkinson's disease (PD), sponsored by University Hospital Tübingen. Started Oct 2026; status: recruiting.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07055087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055087.